Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics

Journal of Virology

Volumn 86, Issue 19, 2012, Pages 10792-10804

  Luongo, Cindy ^a   Winter, Christine C ^a   Collins, Peter L ^a   Buchholz, Ursula J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; DIHYDROLIPOAMIDE DEHYDROGENASE; LIVE VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; TYROSINE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHIMPANZEE; CODON; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE INSERTION; GENE MUTATION; GENETIC STABILITY; MOUSE; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; PHENOTYPE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROPENSITY SCORE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVERSE GENETICS; REVERTANT; TEMPERATURE SENSITIVITY; TEMPERATURE STRESS; VIRAL GENETICS; VIRUS REPLICATION; VIRUS TITRATION;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CELL LINE; CODON; DNA, COMPLEMENTARY; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; MUTATION; MUTATION, MISSENSE; OPEN READING FRAMES; PAN TROGLODYTES; PHENOTYPE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; TEMPERATURE; VACCINES, ATTENUATED;

HUMAN RESPIRATORY SYNCYTIAL VIRUS; PAN; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS; RNA VIRUSES;

EID: 84869007034     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01227-12     Document Type: Article

References (38)

1. Anonymous. 2010. Respiratory syncytial virus activity-United States, July 2008-December 2009. MMWR Morb. Mortal. Wkly. Rep. 59:230-233.
2. Belshe RB, et al. 2004. Evaluation of combined live, attenuated respira-tory syncytial virus and parainfluenza 3 virus vaccines in infants and young children. J. Infect. Dis. 190:2096-2103.
3. Buchholz UJ, Finke S, Conzelmann KK. 1999. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J. Virol. 73:251-259.
4. Bukreyev A, Belyakov IM, Berzofsky JA, Murphy BR, Collins PL. 2001. Granulocyte-macrophage colony-stimulating factor expressed by recom- binant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells. J. Virol. 75:12128-12140.
5. Bukreyev A, Whitehead SS, Murphy BR, Collins PL. 1997. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J. Virol. 71:8973-8982.
6. Collins PL, et al. 1995. Production of infectious human respiratory syn-cytial virus from cloned cDNA confirms an essential role for the transcrip-tion elongation factor from the 5= proximal open reading frame of the M2mRNA in gene expression and provides a capability for vaccine develop- ment. Proc. Natl. Acad. Sci. U. S. A. 92:11563-11567.
7. Collins PL, Murphy BR. 2005. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc. Am. Thorac. Soc. 2:166-173.
8. Connors M, et al. 1992. Cotton rats previously immunized with a chime-ric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immuniza-tion with vaccinia-RSV recombinants or RSV. Vaccine 10:475-484.
9. Crowe JE, Jr. 2001. Respiratory syncytial virus vaccine development. Vaccine 20(Suppl 1):S32-S37.
10. Crowe JE, Jr, Bui PT, Davis AR, Chanock RM, Murphy BR. 1994. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpan-zees. Vaccine 12:783-790.
11. Crowe JE, Jr, et al. 1994. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine 12:691-699.
12. Crowe JE, Jr, et al. 1995. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immu-nogenic, and protective in seronegative chimpanzees, even when RSV an-tibodies are infused shortly before immunization. Vaccine 13:847-855.
13. Crowe JE, Jr, Collins PL, London WT, Chanock RM, Murphy BR. 1993. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mu-tant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine 11:1395-1404.
14. Crowe JE, Jr, Firestone CY, Whitehead SS, Collins PL, Murphy BR. 1996. Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene. Virus Genes 13:269-273.
15. Erwin J, Landon JC. 1992. Spacious biocontainment suites for chimpan- zees in infectious disease research, p 65-69. In Erwin J, Landon JC (ed), Chimpanzee conservation and public health: environments for the future. Diagnon/Bioqual, Rockville, MD.
16. Friedewald WT, Forsyth BR, Smith CB, Gharpure MA, Chanock RM. 1968. Low-temperature-grown RS virus in adult volunteers. JAMA 204: 690-694.
17. Gharpure MA, Wright PF, Chanock RM. 1969. Temperature-sensitive mutants of respiratory syncytial virus. J. Virol. 3:414-421.
18. Karron RA, et al. 2005. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J. Infect. Dis. 191:1093-1104.
19. Karron RA, et al. 1997. Evaluation of two live, cold-passaged, tempera-ture-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J. Infect. Dis. 176:1428-1436.
20. Kim HW, et al. 1971. Clinical and immunological response of infants and children to administration of low-temperature adapted respiratory syncy-tial virus. Pediatrics 48:745-755.
21. Lin YH, et al. 2006. Genetic stability determinants of temperature sensi-tive, live attenuated respiratory syncytial virus vaccine candidates. Virus Res. 115:9-15.
22. Luongo C, et al. 2009. Codon stabilization analysis of the "248" temper-ature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates. Vaccine 27:5667-5676.
23. McAuliffe JM, et al. 2004. Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro. J. Virol. 78:2029-2036.
24. Mejias A, Ramilo O. 2008. Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants. Biologics 2:433-439.
25. Murphy BR, Sotnikov AV, Lawrence LA, Banks SM, Prince GA. 1990. Enhanced pulmonary histopathology is observed in cotton rats immu-nized with formalin-inactivated respiratory syncytial virus (RSV) or puri-fied F glycoprotein and challenged with RSV 3-6 months after immuni-zation. Vaccine 8:497-502.
26. Nair H, et al. 2010. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:1545-1555.
27. Santos J, Risso VA, Sica MP, Ermacora MR. 2007. Effects of serine-to-cysteine mutations on beta-lactamase folding. Biophys. J. 93:1707-1718.
28. Teng MN, et al. 2000. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immuno-genic in chimpanzees. J. Virol. 74:9317-9321.
29. Whitehead SS, et al. 1999. Recombinant respiratory syncytial virus bear- ing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J. Virol. 73:3438-3442.
30. Whitehead SS, Firestone CY, Collins PL, Murphy BR. 1998. A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major de-terminant of the temperature-sensitive and attenuation phenotypes. Vi-rology 247:232-239.
31. Whitehead SS, et al. 1999. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitiv- ity. J. Virol. 73:871-877.
32. Whitehead SS, Juhasz K, Firestone CY, Collins PL, Murphy BR. 1998. Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J. Virol. 72:4467-4471.
33. Witko SE, et al. 2006. An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhadoviruses from a cell line suitable for vaccine development. J. Virol. Methods 135:91-101.
34. Wright PF, et al. 2007. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenu-ated, respiratory syncytial virus vaccines. Vaccine 25:7372-7378.
35. Wright PF, et al. 2000. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J. Infect. Dis. 182:1331-1342.
36. Wright PF, et al. 2006. The interferon antagonist NS2 protein of respira-tory syncytial virus is an important virulence determinant for humans. J. Infect. Dis. 193:573-581.
37. Wright PF, et al. 1976. Evaluation of a live, attenuated respiratory syn-cytial virus vaccine in infants. J. Pediatr. 88:931-936.
38. Wu H, et al. 2007. Development of motavizumab, an ultra-potent anti-body for the prevention of respiratory syncytial virus infection in the up-per and lower respiratory tract. J. Mol. Biol. 368:652-665.